These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 7911998

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
    Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU.
    Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
    [Abstract] [Full Text] [Related]

  • 4. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL.
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [Abstract] [Full Text] [Related]

  • 5. Classification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: defining cohorts for chemoprevention trials.
    Lagios MD.
    J Cell Biochem Suppl; 1996 May; 25():108-11. PubMed ID: 9027606
    [Abstract] [Full Text] [Related]

  • 6. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [Abstract] [Full Text] [Related]

  • 7. Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies.
    Lagios MD, Silverstein MJ.
    Surg Oncol Clin N Am; 1997 Apr; 6(2):385-92. PubMed ID: 9115503
    [Abstract] [Full Text] [Related]

  • 8. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
    Zolota V, Gerokosta A, Melachrinou M, Kominea A, Aletra C, Scopa CD.
    Anticancer Res; 1999 Apr; 19(4B):3269-74. PubMed ID: 10652623
    [Abstract] [Full Text] [Related]

  • 9. Ductal carcinoma in situ of the breast: correlation of pathologic and mammographic features with extent of disease.
    Coombs JH, Hubbard E, Hudson K, Wunderlich C, VanMeter S, Bell JL, Gwin JL.
    Am Surg; 1997 Dec; 63(12):1079-83. PubMed ID: 9393256
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA.
    Breast J; 2009 Dec; 15(2):120-32. PubMed ID: 19292797
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF, Maguire HC, Greene MI, Weiner DB, LiVolsi VA.
    Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
    [Abstract] [Full Text] [Related]

  • 15. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.
    Hieken TJ, Farolan M, D'Alessandro S, Velasco JM.
    Surgery; 2001 Oct; 130(4):593-600; discussion 600-1. PubMed ID: 11602889
    [Abstract] [Full Text] [Related]

  • 16. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
    Boyages J, Delaney G, Taylor R.
    Cancer; 1999 Feb 01; 85(3):616-28. PubMed ID: 10091735
    [Abstract] [Full Text] [Related]

  • 17. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 01; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 18. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
    Maxhimer JB, Pesce CE, Stewart RA, Gattuso P, Prinz RA, Xu X.
    J Am Coll Surg; 2005 Mar 01; 200(3):328-35. PubMed ID: 15737842
    [Abstract] [Full Text] [Related]

  • 19. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.
    Cancer; 2004 Jun 01; 100(11):2317-27. PubMed ID: 15160334
    [Abstract] [Full Text] [Related]

  • 20. 'Revertant' DCIS in human axillary breast carcinoma metastases.
    Barsky SH, Doberneck SA, Sternlicht MD, Grossman DA, Love SM.
    J Pathol; 1997 Oct 01; 183(2):188-94. PubMed ID: 9390032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.